中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2011年
2期
210-213
,共4页
神经节苷脂%早产儿%发育
神經節苷脂%早產兒%髮育
신경절감지%조산인%발육
Monosialoteterahexosyl ganglioside%Premature infant%Development
目的 探讨神经节苷脂对早产儿脑白质损伤神经行为发育的影响.方法 2005年1月至2009年5月我院NICU收治的早产儿共636例,出生后1周内常规行床边头颅B超检查,确诊为早产儿脑白质损伤的患儿40例,随机分为治疗组与对照组,各20例.治疗组在出生后1周内给予单唾液酸四己糖神经节苷脂钠(GM1)20 mg/d加入葡萄糖液中静脉滴注,1疗程为14 d,根据病情使用1～3个疗程,其他治疗措施同对照组.2组脑白质损伤早产儿均于纠正胎龄40周时进行新生儿行为神经测定,在纠正年龄3、12个月时采用婴幼儿智能发育量表,评估神经系统发育情况.结果 治疗组在纠正胎龄40周时的行为神经测定得分为(38.10±0.91)分,明显高于对照组(36.10±1.59)分(t=4.88,P＜0.05).3个月和12个月时进行的智能发育评估显示智力发育指数(MDI)和心理运动发育指数(PDI),治疗组(3个月MDI:91.66±6.38,PDI:87.11±5.57;12个月MDI:104.10±6.45,PDI:100.46±3.87)均明显高于对照组(3个月MDI:81.07±0.72,PDI:81.90±6.70;12个月MDI:98.45±8.57,PDI:95.91±6.59)(P均＜0.05).结论 GM1对早产儿脑白质损伤神经行为发育有促进作用.
目的 探討神經節苷脂對早產兒腦白質損傷神經行為髮育的影響.方法 2005年1月至2009年5月我院NICU收治的早產兒共636例,齣生後1週內常規行床邊頭顱B超檢查,確診為早產兒腦白質損傷的患兒40例,隨機分為治療組與對照組,各20例.治療組在齣生後1週內給予單唾液痠四己糖神經節苷脂鈉(GM1)20 mg/d加入葡萄糖液中靜脈滴註,1療程為14 d,根據病情使用1～3箇療程,其他治療措施同對照組.2組腦白質損傷早產兒均于糾正胎齡40週時進行新生兒行為神經測定,在糾正年齡3、12箇月時採用嬰幼兒智能髮育量錶,評估神經繫統髮育情況.結果 治療組在糾正胎齡40週時的行為神經測定得分為(38.10±0.91)分,明顯高于對照組(36.10±1.59)分(t=4.88,P＜0.05).3箇月和12箇月時進行的智能髮育評估顯示智力髮育指數(MDI)和心理運動髮育指數(PDI),治療組(3箇月MDI:91.66±6.38,PDI:87.11±5.57;12箇月MDI:104.10±6.45,PDI:100.46±3.87)均明顯高于對照組(3箇月MDI:81.07±0.72,PDI:81.90±6.70;12箇月MDI:98.45±8.57,PDI:95.91±6.59)(P均＜0.05).結論 GM1對早產兒腦白質損傷神經行為髮育有促進作用.
목적 탐토신경절감지대조산인뇌백질손상신경행위발육적영향.방법 2005년1월지2009년5월아원NICU수치적조산인공636례,출생후1주내상규행상변두로B초검사,학진위조산인뇌백질손상적환인40례,수궤분위치료조여대조조,각20례.치료조재출생후1주내급여단타액산사기당신경절감지납(GM1)20 mg/d가입포도당액중정맥적주,1료정위14 d,근거병정사용1～3개료정,기타치료조시동대조조.2조뇌백질손상조산인균우규정태령40주시진행신생인행위신경측정,재규정년령3、12개월시채용영유인지능발육량표,평고신경계통발육정황.결과 치료조재규정태령40주시적행위신경측정득분위(38.10±0.91)분,명현고우대조조(36.10±1.59)분(t=4.88,P＜0.05).3개월화12개월시진행적지능발육평고현시지력발육지수(MDI)화심리운동발육지수(PDI),치료조(3개월MDI:91.66±6.38,PDI:87.11±5.57;12개월MDI:104.10±6.45,PDI:100.46±3.87)균명현고우대조조(3개월MDI:81.07±0.72,PDI:81.90±6.70;12개월MDI:98.45±8.57,PDI:95.91±6.59)(P균＜0.05).결론 GM1대조산인뇌백질손상신경행위발육유촉진작용.
Objective To study the effect of monosialoteterahexosyl ganglioside (GM1) on neurobehavioral development in premature infants with white matter damage. Methods A total of 636premature infants who were hospitalized in NICU of two hospitals from Jan 2005 to May 2009 received routine bedside cranial sonography detection before 1 week-aged. Forty premature infants were diagnosed as being premature white matter damage and divided into the treatment group (20 cases ) and the control group (20 cases) randomly. The cases in the treatment group accepted GM1 20 mg additional to 5% glucose solutionthe iv drip, one time per day,for a cycle of 14 d. 1 -3 cycles were given in accordance with patient's condition. Other treatments were same to the control group. All cases were evaluated by neonatal behavioral and neurological assessment (NBNA) at the rectified age of 40 gestational weeks and by Children's Developmental Center of China (CDCC) test at 3 months-aged and 12 months-aged. Results The NBNA scores of the treatment group (38.10±0.91) were significantly higher than the control group (36.10±1.59) at the rectified age of 40 gestational weeks (P＜0.01). The indexes of mental development(MDI) and psychomotor performance development (PDI) by the CDCC tests in the treating group (3 months-aged MDI:91.66±6.38;PDI:87.11±5.57; 12 months-aged MDI:104.10±6.45; PDI:100.46±3.87) were significantly higher than those in the control group (3 months-aged MDI:81.07±0.72; PDI:81.90±6.70; 12 months-aged MDI:98.45±8.57; PDI:95.91±6.59) at 3 months-aged and 12 months-aged ( P ＜ 0. 05 ). Conclusion GM1 can accelerate the neurobehavioral development in premature infants with white matter damage.
